Pressemitteilungen zu dem Thema generic drugs


Unterkategorien

PresseMitteilungen zu dem Schlagwort generic drugs


PCI Synthesis picks up Life Science CMO Leaderships Awards in all six categories

NEWBURYPORT, MA -- (Marketwired) -- 02/01/17 -- PCI Synthesis, Inc. (), a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, today announced that it has won six Life Science Leader CMO Leadership Awards. The company won in every category: Quality, Reliability, Capabilities, Expertise, Compatibility, and Development.This is the fourth consecutive year that PCI Synthesis has been awarded multiple CM ...


01.02.2017

PCI Synthesis Announces the Addition of Its cGMP Advanced Polymer Development and Manufacturing Group

NEWBURYPORT, MA -- (Marketwired) -- 04/19/16 -- PCI Synthesis, Inc. (), a drug substance manufacturer of new chemical entities (NCEs) and generic active pharmaceutical ingredients (APIs), today announced the formation of its cGMP Advanced Polymer Development and Manufacturing Group, which is currently developing and manufacturing more than a dozen advanced polymer-based projects. As the largest independent cGMP contract manufacturing organization (CMO) in New England, the addition of an advance ...


19.04.2016

PCI Synthesis Picks Up Two Life Science Leader Awards

NEWBURYPORT, MA -- (Marketwired) -- 02/09/16 -- PCI Synthesis, Inc. (), a drug substance manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), today announced that it has been recognized as a Life Science Leader CMO Leadership Award recipient in the categories of Reliability (small pharma) and Compatibility (small pharma).This is the third consecutive year that PCI Synthesis has been awarded multiple CMO Leadership Awards and the company has now won an ...


09.02.2016

PCI Synthesis Predicts Key Trends Affecting the Generic Drugs Sector in 2016

NEWBURYPORT, MA -- (Marketwired) -- 12/14/15 -- PCI Synthesis, Inc. (), a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, issued its annual list of trends that will impact the generic drug industry in 2016."The Generic Drug User Fee Amendment known as GDUFA will continue to affect the sector, with higher fees that will hurt smaller generics companies, a speedier approval process, and more ...


14.12.2015

PCI Deepens Connections With the Greater Boston Life Sciences Community With the Signing of a Dozen Local Biotech Customers

NEWBURYPORT, MA -- (Marketwired) -- 06/09/15 -- PCI Synthesis, Inc. (), a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, today announced strengthened ties with the Greater Boston life sciences community with the signing of a dozen local biotech and medtech customers."This year has been one of tremendous growth for PCI," said Ed Price, President of PCI Synthesis. "We''r ...


09.06.2015

PCI Synthesis Sponsors New England CRO/CMO Council

NEWBURYPORT, MA -- (Marketwired) -- 12/16/14 -- PCI Synthesis, Inc. (), a manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, announced that it is a sponsor and steering committee member of the New England CRO/CMO Council (), along with Averica Discovery Services, Organix TGA Sciences, Inc. and CE3.The non-profit New England CRO/CMO Council is open to contract research organizations (CROs) and contract manufactur ...


16.12.2014

PCI Announces 2015 Trends and Predictions

NEWBURYPORT, MA -- (Marketwired) -- 12/09/14 -- PCI Synthesis, Inc. (), a manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products based within the Boston area life science cluster, issued its annual list of trends that it feels will continue to affect the emerging biotech and generic drug industries in 2015.It can take 10 years and more than $2.5 billion to get a drug to market, and more than five years to get a gener ...


09.12.2014

Taglich Brothers Initiates Coverage on Trxade Group, Inc.

NEW YORK, NY -- (Marketwired) -- 11/25/14 -- . announces it initiated coverage of . (OTCQB: TRXD).. (OTCQB: TRXD), based in Lutz, Florida, operates an Internet-based exchange that promotes and enables trading among independent pharmacies and pharmaceutical suppliers (wholesalers). Currently, the company''s market platform is used mainly by around 2,300 retail pharmacies to purchase drugs from 24 wholesalers (supplier to pharmacy). Proprietary software enables users of Trxade' ...


25.11.2014



All members: 9 437
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 58


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.